RedHill to receive $11.7M cash infusion

|By:, SA News Editor

RedHill Biopharma (RDHL -0.4%) has entered into an agreement for an equity placement of $11.7M from Israeli institutional and private investors.

RedHill will use the money for R&D, including developing its RHB-104 treatment for Crohn's disease and RHB-105 for H. pylori infection, both of which are in Phase III studies, and for potential acquisitions. (PR)